Journal
CLINICAL INFECTIOUS DISEASES
Volume 72, Issue 6, Pages 924-938Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciaa194
Keywords
drug allergy; drug challenge; economic evaluation; penicillin allergy
Categories
Funding
- Portuguese Foundation for Science and Technology [PD/BD/129836/2017]
- NIH [K01AI125631]
- AAAAI Foundation
- MGH Claflin Distinguished Scholar Award
- Fundação para a Ciência e a Tecnologia [PD/BD/129836/2017] Funding Source: FCT
Ask authors/readers for more resources
The study projected that penicillin allergy testing is cost-saving in both inpatient and outpatient settings, with potential average savings in United States dollars for patients. Probabilistic sensitivity analysis showed that testing was the less costly option in 75% of simulations, supporting policies promoting widespread testing of patients with a penicillin allergy label.
Background. Having a penicillin allergy label is associated with the use of less appropriate and more expensive antibiotics and increased healthcare utilization. Penicillin allergy testing results in delabeling most allergy claimants and may be cost-saving. This study aimed to project whether penicillin allergy testing in patients reporting a penicillin allergy is cost-saving. Methods. In this economic evaluation study, we built decision models to project the economic impact of 2 strategies for a patient with a penicillin allergy label: (1) perform diagnostic testing (drug challenges, with or without skin tests); and (2) do not perform diagnostic testing. The health service perspective was adopted, considering costs with penicillin allergy tests, and with hospital bed-days/outpatient visits, antibiotic use, and diagnostic testing. Twenty-four base case decision models were built, accounting for differences in the diagnostic workup, setting (inpatient vs outpatient) and geographic region. Uncertainty was explored via probabilistic sensitivity analyses. Results. Penicillin allergy testing was cost-saving in all decision models built. For models assessing the performance of both skin tests and drug challenges, allergy testing resulted in average savings (in United States [US] dollars) of $657 for inpatients (US: $1444; Europe: $489) and $2746 for outpatients (US: $256; Europe: $6045). 75% of simulations obtained through probabilistic sensitivity analysis identified testing as the less costly option. Conclusions. Penicillin allergy testing was projected to be cost-saving across different scenarios. These results are devised to inform guidelines, supporting the adoption of policies promoting widespread testing of patients with a penicillin allergy label.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available